List of Excipients in Branded Drug BSS PLUS

« Back to Dashboard

# BSS PLUS Excipient Strategy and Commercial Opportunities in Ophthalmic Surgical Irrigation

Last updated: August 30, 2026

BSS PLUS is a preservative-free, intraocular irrigating solution used during ophthalmic surgery. Its commercial differentiation comes from the combined use of electrolytes, bicarbonate buffering, citrate and acetate buffering, and reduced glutathione in a sterile two-component presentation. The most attractive opportunities are not conventional formulation patents. They are ready-to-use delivery, validated sterile manufacturing, supply reliability, procedure-specific variants, packaging, and regulatory execution.

What is BSS PLUS and how does its excipient system work?

BSS PLUS is an ophthalmic irrigating solution used to maintain the intraocular environment during procedures such as cataract surgery, corneal surgery, and other anterior-segment interventions. Alcon markets the product as a sterile, nonpyrogenic solution containing physiologically relevant electrolytes and antioxidant components.[1]

The formulation is designed to address several technical requirements at once:

Formulation function	BSS PLUS component or component class	Commercial purpose
Osmotic balance	Sodium chloride and potassium chloride	Supports isotonicity and tissue compatibility
Divalent cations	Calcium chloride and magnesium chloride	Supports ionic conditions relevant to ocular tissues
Buffering	Sodium bicarbonate, sodium acetate and sodium citrate	Helps control pH during storage and use
Antioxidant protection	Reduced glutathione	Limits oxidative stress during intraocular manipulation
Sterile surgical delivery	Aseptic or terminally sterilized container system, depending on product configuration	Reduces microbial and pyrogen risk

The product’s value is created by the entire formulation and presentation. A competitor that copies only the electrolyte profile but changes the buffering system, antioxidant, concentration, container, or reconstitution process may not achieve equivalent performance.

What excipients are used in BSS PLUS?

BSS PLUS contains sodium chloride, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, sodium citrate dihydrate, sodium bicarbonate, and glutathione.[1]

In regulatory terminology, several of these materials may be treated as active ingredients rather than traditional inactive excipients because they define the therapeutic and physiological composition of the irrigating solution. Commercial discussions often use “excipient strategy” more broadly to include the buffer system, antioxidant, tonicity agents, pH modifiers, stabilizers, and packaging materials.

Why glutathione matters

Glutathione is the principal differentiating component relative to basic balanced salt solutions. It is included as a reduced antioxidant. Its presence creates several formulation challenges:

• Oxidation during storage and after reconstitution
• Sensitivity to oxygen exposure and headspace
• Potential degradation from trace metals
• Dependence on pH and temperature
• Need for tight control of concentration and assay impurities
• Potential discoloration or impurity formation over shelf life

Glutathione also creates a supply and quality-control issue. The manufacturer must control reduced-to-oxidized glutathione ratios, degradation products, bioburden, endotoxin, and container-closure compatibility.

Why bicarbonate is commercially important

Bicarbonate improves physiological relevance but complicates manufacturing. Bicarbonate-containing solutions can experience pH drift, carbon dioxide exchange, precipitation risk, and stability changes during sterilization. A two-part presentation can separate components that would otherwise reduce shelf life or create processing problems.

This is a central commercial barrier. A competing product may be chemically simple to describe but difficult to manufacture with a long, reliable shelf life.

What formulation patents protect BSS PLUS?

BSS PLUS is an older ophthalmic product, and the publicly available product-label materials do not establish a current, blocking composition patent that would independently prevent development of a comparable balanced intraocular irrigating solution. The likely commercial protection is based more heavily on product history, regulatory know-how, manufacturing validation, trademarks, hospital purchasing relationships, and supply reliability than on a clearly identifiable active composition patent.[1][2]

Are there current formulation patents?

A definitive patent conclusion requires a current, jurisdiction-specific search of:

• U.S. Patent and Trademark Office records
• WIPO Patentscope
• European Patent Office records
• National patent registers in target launch markets
• Patent assignments and continuations
• Litigation and settlement databases
• Product-specific Orange Book listings

The core electrolyte and glutathione concept is technically old. Any surviving patent position would more likely relate to a narrow formulation, container, reconstitution system, sterilization method, stability profile, manufacturing process, or use limitation.

What intellectual property could a competitor still obtain?

A new entrant could seek protection around:

1. A ready-to-use, single-container formulation with improved glutathione stability.
2. A low-oxygen or oxygen-scavenging container system.
3. A specific bicarbonate-buffered composition with defined pH and osmolality ranges.
4. A reconstitution system that reduces preparation errors.
5. A formulation with lower particulate burden after storage.
6. A modified antioxidant system using glutathione analogs or complementary antioxidants.
7. A product with an extended in-use period after opening.
8. A surgical-packaging configuration that integrates irrigation with other procedure components.
9. A manufacturing process that reduces oxidation and impurity formation.
10. A formulation optimized for endothelial-cell protection or specific ophthalmic procedures.

Patentability would depend on unexpected stability, safety, or clinical performance rather than simply listing known salts in a different order.

What is the FDA regulatory status of BSS PLUS?

BSS PLUS is regulated as a prescription ophthalmic irrigating solution. It is used during surgery and is not a biosimilar product. A follow-on manufacturer would generally evaluate an abbreviated new drug application, a 505(b)(2) application, or another applicable FDA pathway based on the reference product, formulation differences, and available equivalence evidence.[1][3]

The regulatory burden is driven by more than chemical sameness. Key issues include:

• Sterility assurance
• Endotoxin control
• Particulate matter
• pH and osmolality
• Assay and degradation products
• Container-closure integrity
• Stability after preparation
• Compatibility with surgical tubing and instruments
• In-use stability
• Local ocular tolerability
• Equivalence of the complete formulation

Because this is an intraocular product, small changes in pH, ionic composition, particulate burden, or packaging can have material clinical consequences.

Does BSS PLUS have biologic or biosimilar risk?

No. BSS PLUS is a small-molecule aqueous formulation and does not create a conventional biosimilar pathway. Competitive risk comes from generic or follow-on ophthalmic irrigating solutions, hospital-made alternatives, other commercial balanced salt solutions, and procedure-specific irrigation products.

What is the Orange Book status of BSS PLUS?

The FDA Orange Book is relevant only if the product has an applicable listed drug record and associated patent or exclusivity information. Orange Book analysis should distinguish:

• The reference listed drug status
• Any listed patents
• Pediatric exclusivity
• New chemical entity exclusivity
• Three-year clinical investigation exclusivity
• Patent certifications filed by applicants
• Any approved labeling protected by method-of-use claims

BSS PLUS has been marketed for many years. Its principal commercial risk is therefore unlikely to be unresolved new-chemical-entity exclusivity. Any current market protection would require verification against the latest FDA Orange Book and Drugs@FDA records.[2][4]

Are Paragraph IV challenges likely?

A Paragraph IV challenge is possible if an applicant files an ANDA referencing a listed product with relevant patents. The commercial attractiveness depends on whether the reference product has enforceable listed patents and whether the applicant can demonstrate pharmaceutical equivalence and bioequivalence or another acceptable form of equivalence.

For BSS PLUS, the higher-risk issues may be technical rather than patent-centered:

• Whether the proposed formulation is pharmaceutically equivalent
• Whether glutathione oxidation differs materially
• Whether the product has the same dosage form and route
• Whether the container system changes product performance
• Whether clinical or in-use data are needed
• Whether the applicant can reproduce the reference product’s stability profile

A weak patent estate does not eliminate regulatory barriers.

When does BSS PLUS lose exclusivity?

BSS PLUS appears to be a mature product with long-expired conventional exclusivity periods. The relevant commercial question is not when basic exclusivity expires, but whether any later patent, regulatory protection, manufacturing barrier, shortage-related advantage, or contractual hospital position remains.

There is no biosimilar exclusivity period. A generic entrant would not need to wait for biologic reference-product exclusivity. Market entry would instead depend on FDA approval, manufacturing capacity, quality validation, and customer conversion.

What generic entry risks exist for BSS PLUS?

Generic entry risk is moderate in theory and operationally difficult in practice.

Risk factor	Effect on incumbent	Effect on entrant
Mature electrolyte composition	Limits broad composition protection	Makes basic formulation design accessible
Glutathione oxidation	Supports differentiation and quality barriers	Raises development and stability costs
Sterile ophthalmic manufacturing	Protects supply reliability	Requires specialized facilities and validation
Hospital switching costs	Supports incumbent retention	Slows formulary conversion
Product shortages	Can expose incumbent weakness	Creates opening for qualified suppliers
Low unit price relative to development cost	Limits price premium	Can weaken return on investment
Surgical criticality	Rewards reliable supply	Increases qualification requirements

The most realistic generic launch would initially target hospitals and ambulatory surgery centers with a price-based offer, supported by equivalent composition, validated stability, and reliable delivery. A direct-to-consumer strategy is irrelevant because the product is purchased and used by surgical providers.

What commercial opportunities exist in BSS PLUS excipient innovation?

Ready-to-use presentation

A single-container, ready-to-use product could reduce preparation steps and pharmacy or operating-room handling. The main development challenge is preserving bicarbonate and reduced glutathione stability without shortening shelf life.

A successful product would need to demonstrate:

• Long-term stability
• Low oxygen exposure
• Acceptable pH drift
• No clinically relevant precipitation
• Sterility through expiry
• Low particulate levels
• Simple operating-room use

Improved antioxidant systems

A competitor could investigate glutathione concentration, stabilization, or complementary antioxidant systems. The opportunity is strongest where a formulation can show measurable protection against oxidative damage without causing ocular toxicity or compromising sterilization.

Potential approaches include:

• Higher reduced-glutathione retention
• Lower oxidized-glutathione formation
• Trace-metal control
• Alternative antioxidant combinations
• Oxygen-reduced headspace
• Light-protective packaging

Premium procedure-specific irrigants

Products could be optimized for:

• Cataract surgery
• Corneal transplantation
• Vitreoretinal procedures
• Glaucoma surgery
• Endothelial keratoplasty
• Pediatric ophthalmic surgery

A procedure-specific product may command a premium if it offers clinically meaningful handling, visualization, tissue-protection, or compatibility benefits. Method-of-use patents could be more defensible than a broad salt composition if supported by clinical evidence.

Packaging and operating-room workflow

The strongest near-term opportunity may be packaging rather than chemistry. Innovations include:

• Integrated spike and transfer systems
• Low-oxygen containers
• Reduced-volume formats
• Single-use surgical kits
• Clear labeling for reconstitution
• Tamper-evident packaging
• Improved port design
• Packaging compatible with automated irrigation systems

Packaging patents can create differentiation even where the solution chemistry is difficult to protect.

Supply-chain and contract manufacturing

Hospital customers value continuity. A qualified manufacturer with dual-source raw materials, regional fill-finish capacity, validated sterilization, and documented contingency inventory can compete without owning a major composition patent.

Critical raw materials include pharmaceutical-grade salts, bicarbonate, and glutathione. Supplier qualification should address identity, impurities, endotoxin, microbial burden, oxidation state, and lot-to-lot variability.

Which companies are challenging BSS PLUS?

The primary competitive set includes:

• Alcon, as the established BSS PLUS supplier
• Manufacturers of balanced salt solutions
• Generic ophthalmic irrigating-solution developers
• Contract manufacturers with sterile ophthalmic capability
• Suppliers of surgical irrigation products and procedure packs

Public information does not establish a current, material patent litigation campaign or settlement agreement specifically involving BSS PLUS. Competitive intelligence should focus on FDA approvals, drug shortages, ANDA filings, procurement awards, recalls, manufacturing transfers, and hospital formulary changes rather than assuming litigation is the main market trigger.

How does BSS PLUS compare with basic balanced salt solution?

Attribute	BSS PLUS	Basic balanced salt solution
Electrolyte system	Physiologically balanced	Physiologically balanced
Glutathione	Included	Often absent
Bicarbonate complexity	Higher	May be lower
Stability challenge	Higher	Generally simpler
Manufacturing cost	Higher	Lower
Differentiation	Antioxidant and formulation profile	Price, availability, and compatibility
Regulatory development burden	Higher for comparable antioxidant system	Lower for simpler composition
Premium opportunity	Procedure protection and stability	Cost-efficient routine irrigation

BSS PLUS is better positioned as a premium formulation than as a commodity irrigation fluid. A low-cost competitor can erode share if hospitals perceive no clinical or workflow advantage, but the incumbent retains an advantage where surgeons prefer a known antioxidant-containing product.

What revenue exposure does BSS PLUS represent?

Alcon reports ophthalmology revenue by broader business categories and does not generally disclose standalone BSS PLUS revenue in public financial reporting.[5] Product-level revenue exposure therefore cannot be calculated reliably from company filings.

The product’s strategic value may exceed its reported sales contribution because it supports Alcon’s surgical portfolio, distributor relationships, and operating-room presence. Revenue sensitivity is most likely tied to:

• Cataract procedure volumes
• Ambulatory surgery center purchasing
• Hospital contracts
• Product availability
• Competitor shortages
• Conversion to lower-cost irrigation products
• Regional tender pricing

Key Takeaways

• BSS PLUS is differentiated by its electrolyte, bicarbonate, citrate, acetate, and reduced-glutathione system.
• The most important technical barrier is maintaining glutathione and bicarbonate stability in a sterile ophthalmic product.
• The product is a mature small-molecule formulation with no biosimilar pathway.
• Conventional exclusivity is likely no longer the principal commercial protection.
• Current Orange Book patent status and any Paragraph IV exposure require live, product-specific verification.
• New entrants can compete through ready-to-use packaging, stable antioxidant formulations, procedure-specific products, and supply reliability.
• The strongest patent opportunities are likely narrow claims covering stability, packaging, manufacturing, or clinically supported methods of use.
• BSS PLUS revenue is not separately disclosed by Alcon, so product-specific revenue exposure cannot be quantified from public filings.
• Generic entry is technically feasible but requires specialized sterile manufacturing, tight quality control, and hospital qualification.
• The commercial opportunity is strongest in premium, workflow-oriented ophthalmic irrigation rather than undifferentiated commodity pricing.

FAQs

Can glutathione be replaced in a BSS PLUS follow-on product?

Yes, but replacing glutathione would create a materially different formulation and could increase FDA comparability, safety, and clinical-evidence requirements. A follow-on product seeking close equivalence would generally preserve the reference product’s glutathione function and concentration profile.

Is BSS PLUS a drug or a medical device?

BSS PLUS is regulated as an ophthalmic drug product used for intraocular irrigation. The container and delivery components may be regulated separately or as part of the drug presentation.

Can BSS PLUS be compounded by hospitals?

Hospital compounding of intraocular irrigating solutions carries significant sterility, endotoxin, particulate, and formulation risks. Commercial products are generally preferred for routine surgical use because they have validated manufacturing and stability controls.

What is the most defensible patent strategy for a BSS PLUS competitor?

The strongest strategy would likely combine a narrow formulation patent with container-closure, low-oxygen packaging, manufacturing-process, and method-of-use claims supported by stability and clinical data.

Would a shortage create a rapid market-entry opportunity?

Yes. A shortage can accelerate hospital qualification of alternative suppliers, but ophthalmic surgical products still require regulatory approval, quality documentation, purchasing qualification, and surgeon acceptance before meaningful substitution occurs.

References

1. U.S. Food and Drug Administration. (n.d.). BSS PLUS intraocular irrigating solution: Prescribing information. Alcon Laboratories, Inc.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptides. FDA guidance and abbreviated application principles.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
5. Alcon Inc. (2024). Annual report and Form 10-K. Alcon Inc.